Lung adenocarcinoma-related gene signatures and application thereof
A lung adenocarcinoma and gene technology, applied in the field of lung adenocarcinoma-related gene labeling, to achieve the effect of reducing medical costs and avoiding overdose
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0030] System validation using TCGA public database of lung adenocarcinoma patients:
[0031] The prognostic scoring system was applied to 517 TCGA lung adenocarcinoma patients with survival data ( image 3 ). Prognostic scores were used to predict the probability of survival for each individual patient. We divided the patients into three groups according to the 27-gene signature prognostic score, namely, good prognosis, intermediate prognosis and poor prognosis. Such as image 3 As shown in B, in the two exemplary test groups, the overall survival rate of patients carrying the "good" prognostic gene signature was significantly longer than that of the "low" group (HR confidence interval higher than "1") (Fig. 3B, bottom panel) . In the former, more than 60% of patients are still alive after 75 months, while in the latter, all patients die within 50 months or only 10% of patients survive.
Embodiment 2
[0033] Survival analysis of patients with lung adenocarcinoma using the GSE public database:
[0034] Using the same method, we verified the application value of the prognostic scoring system in four public databases of lung adenocarcinoma, GSE42127, GSE31210, GSE37745 and GSE30219 ( Figure 4 and Table 3). Different from the cancer gene database TCGA established by RNA sequencing, the tissue gene expression values of these databases are determined by Affymetrix chip technology. Figure 4 The Kaplan-Meier overall survival curve of A shows that the scoring system of the present invention can successfully predict the prognosis of lung adenocarcinoma patients in the above-mentioned database. Finally, we used Cox regression to understand whether the prognostic score of the present invention is independent of other clinical information including patient age, gender and tumor stage (Table 3), and concluded that our prognostic score was independently significantly correlated with ...
Embodiment 3
[0036] Comparing the performance of other lung adenocarcinoma prognostic gene signatures with the 27-gene signature of the present invention:
[0037] The literature has shown the correlation between multiple gene groups and the prognosis of lung adenocarcinoma by using the method of gene expression difference. A key question is whether our 27-gene scoring system outperforms these genomic signatures. Using the same specimen or method, we used three previously reported lung adenocarcinoma gene signatures to calculate prediction scores, including a 15-genome (ZhuCQ et al., Prognostic and predictive gene signature for adjuvant chemotherapy inresected non-small-cell lung cancer.Journal of Clinical Oncology.2010; 28:4417-24), 14-gene signature (Kratz JR et al., A practical molecular assay to predict survival in resected non-squamous, non-small cell lung cancer: development and international validation studies.Lancet 2012; 379:823-32) and 31-gene signature (WistubaII et al., Valida...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com